Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Change in Receivables (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Change in Receivables for 3 consecutive years, with -$1.4 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables changed N/A to -$1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.5 million for FY2025, N/A changed from the prior year.
  • Change in Receivables for Q4 2025 was -$1.4 million at Outlook Therapeutics, down from -$260491.0 in the prior quarter.
  • The five-year high for Change in Receivables was -$260491.0 in Q3 2025, with the low at -$1.4 million in Q4 2025.